Regeneron Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1988-01-01

Employees: 13.4K

Market Cap: $132.4B

Website: http://www.regeneron.com

Introduction: Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Clinical Trials

A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works.

Phase 3

Recruiting

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Interventions: Drug: Pozelimab
Drug: Cemdisiran

First Posted Date: 2023-02-27

Last Posted Date: 2025-05-01

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 202

Registration Number: NCT05744921

Locations: 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
🇭🇺
Semmelweis University/Semmelweis Egyetem, Budapest, Hungary
🇮🇳
Rajiv Gandhi Cancer Institute & Research Center (RGCIRC) - Rohini Campus, New Delhi, Delhi, India

and more 31 locations

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

Phase 3

Recruiting

Conditions: Relapsed Refractory Multiple Myeloma (RRMM)

Interventions: Drug: Linvoseltamab
Drug: Elotuzumab
Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2023-02-15

Last Posted Date: 2025-05-13

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 380

Registration Number: NCT05730036

Locations: 🇮🇱
The Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
🇧🇷
Instituto DOr de Pesquisa e Ensino, Sao Paulo, Brazil
🇧🇷
AC Camargo Cancer Center, Sao Paulo, Brazil

and more 154 locations

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

Phase 1

Recruiting

Conditions: B-cell Non-Hodgkins Lymphoma (B-NHL)

Interventions: Drug: Odronextamab
Drug: REGN5837

First Posted Date: 2023-01-13

Last Posted Date: 2025-04-27

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 91

Registration Number: NCT05685173

Locations: 🇪🇸
University Hospital and Research Institute, Madrid, Spain
🇬🇧
The Christie, Manchester, United Kingdom
🇺🇸
University of California Los Angeles (UCLA) Medical Center, Santa Monica, California, United States

and more 17 locations

Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

Completed

Conditions: Relapsed and Refractory Multiple Myeloma (RRMM)

Interventions: Other: Non-Interventional

First Posted Date: 2023-01-06

Last Posted Date: 2025-04-25

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 62

Registration Number: NCT05673967

Locations: 🇺🇸
Regeneron Research Facility, Tarrytown, New York, United States

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Non-Alcoholic Fatty Liver Disease (NAFLD)

Phase 1

Active, not recruiting

Conditions: Non-alcoholic Fatty Liver Disease (NAFLD)
Healthy Volunteers

Interventions: Drug: ALN-PNP - Part A
Drug: ALN-PNP - Part B
Drug: Placebo (PB)

First Posted Date: 2022-12-13

Last Posted Date: 2025-03-18

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 23

Registration Number: NCT05648214

Locations: 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States
🇺🇸
Velocity Clinical research, Los Angeles, California, United States
🇺🇸
Genoma Research Group ,Inc, Miami, Florida, United States

and more 3 locations

A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants

Phase 2

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: Apixiban
Drug: REGN9933
Drug: Enoxaparin

First Posted Date: 2022-11-16

Last Posted Date: 2024-06-06

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 373

Registration Number: NCT05618808

Locations: 🇧🇬
MBAL Heart and Brain Hospital, Pleven, Bulgaria
🇧🇪
Ziekenhuis Oost-Limburg- Campus Sint-Jan, Genk, Limburg, Belgium
🇭🇺
Department of Orthopedics, Somogy County Mór Kaposi Teaching Hospital, Kaposvar, Hungary

and more 13 locations

A Compassionate Use (CU) Program of Odronextamab

Conditions: Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Diffuse Large B-Cell Lymphoma (DLBCL)
B-Cell Non-Hodgkin Lymphoma (NHL)
High-Grade B-Cell Lymphoma (HGBCL)

First Posted Date: 2022-11-16

Last Posted Date: 2025-01-27

Lead Sponsor: Regeneron Pharmaceuticals

Registration Number: NCT05619367

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Phase 3

Active, not recruiting

Conditions: Melanoma

Interventions: Drug: Fianlimab
Drug: Pembrolizumab
Drug: Cemiplimab
Drug: Placebo

First Posted Date: 2022-11-08

Last Posted Date: 2025-05-13

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 1564

Registration Number: NCT05608291

Locations: 🇫🇷
Sainte Catherine Institut du Cancer Avignon Provence, Avignon, France
🇫🇷
N_Hôpital Ambroise-Paré, Boulogne Billancourt, France
🇫🇷
CHU Estaing, Clermont Ferrand, France

and more 208 locations

A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: REGN7508 (IV)
Drug: REGN7508 (SC)
Drug: Matching Placebo (SC)
Drug: Matching Placebo (IV)

First Posted Date: 2022-11-02

Last Posted Date: 2024-09-30

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 80

Registration Number: NCT05603195

Locations: 🇬🇧
Labcorp Clinical Research Unit, Leeds, United Kingdom

Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial

Phase 4

Completed

Conditions: Moderate-to-Severe Atopic Dermatitis
Atopic Eczema

Interventions: Drug: dupilumab
Other: Topical emollient (moisturizer)

First Posted Date: 2022-10-21

Last Posted Date: 2024-12-10

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 124

Registration Number: NCT05590585

Locations: 🇺🇸
Skin and Cancer Associates, LLP, Miami, Florida, United States
🇺🇸
C2 Research Center, LLC, Montgomery, Alabama, United States
🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

and more 27 locations

Home Terms & Conditions Privacy Policy